STAT5B and chronic myelogenous leukemia, BCR-ABL1 positive: This is also supported by previous works showing that STAT5B but not STAT5A plays a key role in BCR-ABL-induced leukemogenesis and in the sensitivity of CML cells to TKI treatment [41,42].